ABSTRACT
INTRODUCTION
Osteoporosis is still an under-recognized problem in men [1] . In a recent updated systematic review summarizing the evidence of pharmacologic treatments to prevent fractures in primary osteoporosis, the author only found one randomized trial of men with osteoporosis designed with a primary fracture reduction outcome [2] . Although the incidence of osteoporosis in men is less frequent compared to that in women, a large number of men have osteoporosis and their health is threatened by this condition. Approximately 20% of all clinical vertebral fractures and 30% of all hip fractures occur in men, but mortality in men with vertebral or hip fractures is significantly higher than in women [3] [4] [5] [6] .
In more than 50% of men with osteoporosis, the disease is the result of an identifiable cause that results in bone loss and bone fragility. The most common causes of secondary osteoporosis in men are glucocorticoid excess, hypogonadism, and excessive alcohol consumption, which are believed to cause bone resorption to outweigh bone formation, resulting in bone loss and fractures in men [3, 7, 8] . Men also suffer bone loss naturally, which is more common with deficient testosterone or estradiol level and is accelerated after the age of 70 years [1] .
Three bisphosphonates, namely alendronate, risedronate, and zoledronic acid, are recommended for treating men with osteoporosis in the 2012 clinical practice guideline of the Endocrine Society [9] . Although bisphosphonates cannot remove the secondary causes, they may prevent bone loss and fractures by inhibiting bone resorption [10] .
Bisphosphonates have positive effects on bone mass density and bone biomarkers, and reduce vertebral fractures in men with osteoporosis [11] .
In order to clarify the comparative efficacy of different bisphosphonates in preventing fractures, several network meta-analyses and multiple treatment analyses were carried out [12] [13] [14] . However, none of them specifically addressed men with osteoporosis and these studies primarily focused on the use of bisphosphonates in treating postmenopausal osteoporosis. Therefore, we performed this systematic review with network meta-analyses to evaluate the comparative efficacy of bisphosphonates in men with osteoporosis. We report the outcomes for osteoporosis with different causes separately, since patients with different types of osteoporosis may respond to bisphosphonates differently.
METHODS

Search Strategy
We searched for randomized controlled trials in 
Data Extraction and Quality Assessment
Two reviewers (JZ, XZ) independently extracted baseline data and assessed the studies' methodological quality using the risk of quality assessment tool recommended by the Cochrane Handbook for randomized controlled trials [17] . The authors considered random sequence generation, allocation concealment, blinding of participants, caregivers, fracture outcome assessors, incomplete information, selective reporting, and other bias. The criteria were all classified into low, high, or unclear risk of bias on the basis of guidance from The Cochrane Collaboration [17] .
Data Synthesis and Analysis
We excluded comparisons with zero events in both groups from the relevant analysis since such comparisons provided no information on the magnitude of the treatment effect [18] .
We conducted network meta-analyses with a frequentist model [19] [20] [21] using STATA release 13.1 [22] . We based direct probability statements on 50,000-simulation iterations to identify the best and most representative data, assuming comparable interstudy variances for all treatment effects for the same outcomes. The assessment of statistical heterogeneity in the entire network was based on the magnitude of the heterogeneity variance parameter (s 2 ) estimated from the network meta-analysis models [23] . Inconsistency was checked if a comparison loop existed [24] [25] [26] . We included the randomized but open-label studies in the network meta-analyses for sensitivity analyses. We also performed a sensitivity analyses with a Bayesian model [27] to check on the robustness of the network meta-analyses.
Pairwise meta-analyses were performed in Review Manager 5.2 using the random effect model for each outcome comparing each bisphosphonate with placebo. For outcomes in which studies reported zero events in one treatment arm, we added 0.5 to the numerator and 1 to the denominator. Results were expressed as an odds ratio (OR) with 95% confidence intervals (CI). We assessed and quantified heterogeneity using Chi 2 test and I 
RESULTS
After screening 2653 citations and 683 clinical trials ( Fig. 1 
DISCUSSION
In this systematic review, we summarized the comparative efficacy of preventing fracture with bisphosphonates in men with osteoporosis by integrating all available direct and indirect evidence. We found that zoledronic acid had the highest probability to rank best in preventing vertebral fracture in primary osteoporosis, and risedronate had the highest probability to rank best in preventing non-vertebral fracture in both primary osteoporosis and corticosteroid-induced osteoporosis. Our summary of the results also [37] .
Although cancer-related osteoporosis was not considered in our analysis, as fracture in cancer-associated bone disease may result from causes other than osteoporosis [15] , other meta-analyses [40, 41] found that zoledronic acid was effective in preventing fractures for patients under androgen deprivation therapy for prostate cancer and nonmetastatic prostate cancer. No other randomized controlled study investigating the efficacy of bisphosphonates in men with osteoporosis was found.
Network meta-analyses focusing on the use of bisphosphonates in treating postmenopausal women should be considered when treating men with osteoporosis using bisphosphonates.
Compared with our study, these network meta-analyses have a larger sample size, therefore the estimates could be more precise to show comparative efficacy among different bisphosphonates. The study by Jansen et al. [13] found that zoledronic acid and risedronate ranked the highest in preventing vertebral fracture and non-vertebral fracture, respectively, in postmenopausal women, which is consistent with our systematic review regarding their efficacy in men. Until adequate evidence is available to better evaluate the comparative efficacy of preventing fracture with bisphosphonates in men, we can also refer to the available studies for postmenopausal women.
Our study has a few improvements compared with the similar network meta-analysis [42] With these approaches, our analysis has lower heterogeneity and fewer confounding factors.
Limitations exist in this study. Firstly, our estimates have uncertainty. The evidence for using bisphosphonates to treat men with osteoporosis is inadequate, and the sample sizes of the eligible studies are mostly small. Secondly, we did not include some studies of bisphosphonates preventing fracture in men [43, 44] , because women were also included in these studies and we could not extract the data of men only. Thirdly, somewhat different assessment criteria of vertebral fracture were applied in included studies. Semiquantitative methods and quantitative morphometric methods [16] were assumed equally sensitive in our meta-analysis. Last, heterogeneity from the study design may exist as only two studies considered the outcome of fracture as their primary outcome, while others considered the outcome of fracture as a secondary outcome. 
